SG10201810615VA - Pd-1 / pd-l1 inhibitors for the treatment of cancer - Google Patents

Pd-1 / pd-l1 inhibitors for the treatment of cancer

Info

Publication number
SG10201810615VA
SG10201810615VA SG10201810615VA SG10201810615VA SG10201810615VA SG 10201810615V A SG10201810615V A SG 10201810615VA SG 10201810615V A SG10201810615V A SG 10201810615VA SG 10201810615V A SG10201810615V A SG 10201810615VA SG 10201810615V A SG10201810615V A SG 10201810615VA
Authority
SG
Singapore
Prior art keywords
cancer
inhibitors
treatment
subject
ligand
Prior art date
Application number
SG10201810615VA
Inventor
Jean-Marie Cuillerot
Anja Von Heydebreck
Guojun Yuan
Original Assignee
Merck Patent Gmbh
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Pfizer filed Critical Merck Patent Gmbh
Publication of SG10201810615VA publication Critical patent/SG10201810615VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PD-1 / PD-L1 INHIBITORS FOR THE TREATMENT OF CANCER The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1. ( No figure )
SG10201810615VA 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer SG10201810615VA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562121025P 2015-02-26 2015-02-26
US201562133721P 2015-03-16 2015-03-16
US201562160291P 2015-05-12 2015-05-12
US201562215394P 2015-09-08 2015-09-08
US201562254424P 2015-11-12 2015-11-12

Publications (1)

Publication Number Publication Date
SG10201810615VA true SG10201810615VA (en) 2019-01-30

Family

ID=55588542

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201706918YA SG11201706918YA (en) 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer
SG10201810615VA SG10201810615VA (en) 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201706918YA SG11201706918YA (en) 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer

Country Status (15)

Country Link
US (2) US10800846B2 (en)
EP (2) EP4279087A3 (en)
JP (3) JP6885869B2 (en)
KR (1) KR20170132171A (en)
CN (2) CN112263677A (en)
AU (3) AU2016222928B2 (en)
BR (1) BR112017018234A2 (en)
CA (1) CA2977767C (en)
IL (2) IL278423B2 (en)
MX (2) MX2017010773A (en)
NZ (1) NZ733854A (en)
RU (1) RU2714233C2 (en)
SG (2) SG11201706918YA (en)
TW (2) TWI748942B (en)
WO (1) WO2016137985A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012344260B2 (en) * 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JP6885869B2 (en) 2015-02-26 2021-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ PD-1 / PD-L1 Inhibitors for Treating Cancer
MA42971A (en) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
AU2016280003B2 (en) 2015-06-16 2021-09-16 Merck Patent Gmbh PD-L1 antagonist combination treatments
IL293385A (en) 2015-08-11 2022-07-01 Omniab Inc Novel anti-pd-1 antibodies
CN107949573B (en) 2015-09-01 2022-05-03 艾吉纳斯公司 anti-PD-1 antibodies and methods of use thereof
JP6925337B2 (en) 2015-12-07 2021-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Aqueous pharmaceutical preparation containing anti-PD-L1 antibody avelumab
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
KR102543015B1 (en) 2016-06-17 2023-06-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compounds, compositions and methods for the prevention and/or treatment of cancer
TN2019000081A1 (en) * 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to pd-1 and functional fragment thereof
BR112019006504A2 (en) * 2016-10-06 2019-06-25 Merck Patent Gmbh Avelumab Dosage Regimen For Cancer Treatment
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
KR20190125363A (en) 2017-03-06 2019-11-06 메르크 파텐트 게엠베하 Aqueous Anti-PD-L1 Antibody Formulations
EP3372615A1 (en) 2017-03-06 2018-09-12 Merck Patent GmbH Composition comprising avelumab
EP3600410A1 (en) * 2017-03-30 2020-02-05 Merck Patent GmbH Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
BR112019025188A2 (en) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
JP2020536887A (en) * 2017-10-13 2020-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Combination of PARP inhibitor and PD-1 binding antagonist
WO2019118855A1 (en) * 2017-12-14 2019-06-20 The Trustees Of The University Of Pennsylvania Compounds and compositions for prevention and/or treatment of cancer
EP3768713A2 (en) * 2018-03-22 2021-01-27 Keires AG Antagonistic pd-1, pd-l1 and lag-3 binding proteins
SG11202012426WA (en) * 2018-06-13 2021-01-28 Merck Patent Gmbh Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
SG11202105078XA (en) * 2018-11-14 2021-06-29 Bayer Ag Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
US11851490B2 (en) 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
US20210169979A1 (en) * 2019-12-05 2021-06-10 The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges System and method for sonosensitized cancer immunotherapy with nanoparticles
US20230058779A1 (en) * 2020-01-02 2023-02-23 Merck Sharp & Dohme Llc Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
TW202404634A (en) * 2022-04-05 2024-02-01 美商安進公司 Treatment of gastric cancer

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000475A (en) 1908-12-31 1911-08-15 Rodney Robert Woodson Coal-mining pick.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
JPH07263576A (en) 1994-03-25 1995-10-13 Hitachi Ltd Semiconductor integrated circuit device and manufacture thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
RU2341263C2 (en) 2003-04-03 2008-12-20 Пфайзер Инк. Medicinal forms containing ag013736
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
RU2007114112A (en) 2004-11-02 2008-12-10 Пфайзер Инк. (US) METHOD FOR PRODUCING INDOSOLIC COMPOUNDS
RU2007116107A (en) 2004-11-02 2008-11-10 Пфайзер Инк. (US) METHODS FOR OBTAINING INDOSOLIC COMPOUNDS
CN101052633A (en) 2004-11-02 2007-10-10 辉瑞大药厂 Methods of preparing indazole compounds
WO2006048746A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for the removal of heavy metals
EP1819696A1 (en) 2004-11-02 2007-08-22 Pfizer, Inc. Polymorphic forms of 6-2-(methylcarbamoyl)phenysulfanyl|-3-e-2-(pyridin-2-yl)ethenyl indazole
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JP2008540629A (en) 2005-05-19 2008-11-20 ファイザー・インク Pharmaceutical composition comprising amorphous VEGF-R inhibitor
AU2006265108C1 (en) * 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
AU2008236444B2 (en) 2007-04-05 2012-06-28 Pfizer Products Inc. Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-E- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
KR101577843B1 (en) 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 Binding molecules to the human ox40 receptor
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
RS54233B1 (en) * 2008-08-25 2015-12-31 Amplimmune Inc. Compositions of pd-1 antagonists and methods of use
CN102203125A (en) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1 antagonists and methods of use thereof
CN108484767B (en) 2008-09-26 2022-01-14 达纳-法伯癌症研究公司 Human anti-PD-1, PD-L1 and PD-L2 antibodies and uses thereof
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
KR101934071B1 (en) 2009-11-24 2019-01-02 메디뮨 리미티드 Targeted binding agents against b7-h1
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
RU2013114360A (en) 2010-08-31 2014-10-10 Дженентек, Инк. BIOMARKERS AND TREATMENT METHODS
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
CN106432506A (en) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 Multivalent and monovalent multispecific complexes and their uses
ES2708669T3 (en) 2011-08-01 2019-04-10 Hoffmann La Roche Cancer treatment procedures using PD-1 axis-binding antagonists and MEK inhibitors
AU2012313885A1 (en) 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide
RU2014116407A (en) 2011-11-11 2015-12-20 Пфайзер Инк. N-METHYL-2- [3 - ((E) -2-PYRIDIN-2-IL-VINYL) -1H-INDAZOL-6-YLSULFANIL] -BENZAMIDE FOR THE TREATMENT OF CHRONIC MYELOID LEukemia
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
ES2740358T3 (en) 2012-02-06 2020-02-05 Providence Health & Services Oregon Method of monitoring cancer treatment with OX40 agonists
WO2013164754A2 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
MY186099A (en) 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
HUE035503T2 (en) * 2012-10-02 2018-05-02 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
RU2701378C2 (en) 2013-03-15 2019-09-26 Дженентек, Инк. Biomarkers and methods of treating associated with pd-1 and pd-l1 conditions
CA2899577C (en) 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014167088A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2014197369A1 (en) * 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
DK3043816T3 (en) 2013-09-11 2019-10-14 Medimmune Ltd ANTI-B7-H1 ANTIBODIES FOR TREATMENT OF TUMORS
AR097584A1 (en) 2013-09-12 2016-03-23 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
CA2926856A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
CN105828834A (en) * 2013-11-05 2016-08-03 同源生物服务股份有限公司 Combinations of checkpoint inhibitors and therapeutics to treat cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
KR20210063475A (en) 2013-11-07 2021-06-01 데시페라 파마슈티칼스, 엘엘씨. Methods for inhibiting tie2 kinase useful in the treatment of cancer
EP3079699A4 (en) 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
US9045545B1 (en) * 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
SG11201604875PA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG11201604995YA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
PT3102605T (en) 2014-02-04 2019-02-12 Pfizer Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CA2942039A1 (en) 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
EP3572430A3 (en) 2014-03-05 2020-02-12 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN115590953A (en) 2014-05-15 2023-01-13 百时美施贵宝公司（Us） Treatment of lung cancer using a combination of an anti-PD-1 antibody and another anti-cancer agent
JP7032929B2 (en) * 2014-07-11 2022-03-09 ヴェンタナ メディカル システムズ， インク． Anti-PD-L1 antibody and its diagnostic use
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
KR20170066546A (en) 2014-10-03 2017-06-14 노파르티스 아게 Combination therapies
AU2015333687B2 (en) * 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP3212670B1 (en) * 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
KR20170096112A (en) 2014-11-17 2017-08-23 제넨테크, 인크. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR20170101925A (en) 2014-12-02 2017-09-06 셀진 코포레이션 Combination therapy
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
JP6885869B2 (en) 2015-02-26 2021-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ PD-1 / PD-L1 Inhibitors for Treating Cancer
AU2016280003B2 (en) 2015-06-16 2021-09-16 Merck Patent Gmbh PD-L1 antagonist combination treatments
JP2018529719A (en) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Combination of PD-1 system binding antagonist and ALK inhibitor for treating ALK negative cancer
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
BR112019006504A2 (en) 2016-10-06 2019-06-25 Merck Patent Gmbh Avelumab Dosage Regimen For Cancer Treatment
EP3600410A1 (en) * 2017-03-30 2020-02-05 Merck Patent GmbH Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
IL278423B1 (en) 2023-12-01
AU2016222928B2 (en) 2021-05-13
EP3262073A1 (en) 2018-01-03
JP7116113B2 (en) 2022-08-09
TWI755791B (en) 2022-02-21
EP4279087A3 (en) 2024-01-31
EP4279087A2 (en) 2023-11-22
AU2021204217A1 (en) 2021-07-15
WO2016137985A1 (en) 2016-09-01
RU2017133273A3 (en) 2019-07-24
US20180244781A1 (en) 2018-08-30
CA2977767A1 (en) 2016-09-01
SG11201706918YA (en) 2017-09-28
CN107405401B (en) 2022-02-01
JP2020114840A (en) 2020-07-30
IL254131B (en) 2021-02-28
JP2018508512A (en) 2018-03-29
TW201639597A (en) 2016-11-16
KR20170132171A (en) 2017-12-01
CN107405401A (en) 2017-11-28
AU2016222928A1 (en) 2017-10-12
RU2714233C2 (en) 2020-02-13
CA2977767C (en) 2024-04-09
JP6885869B2 (en) 2021-06-16
BR112017018234A2 (en) 2018-04-17
TWI748942B (en) 2021-12-11
JP2021178822A (en) 2021-11-18
CN112263677A (en) 2021-01-26
US20200362040A1 (en) 2020-11-19
MX2022001757A (en) 2022-03-11
MX2017010773A (en) 2018-03-15
IL254131A0 (en) 2017-10-31
NZ733854A (en) 2022-07-01
TW202110480A (en) 2021-03-16
US10800846B2 (en) 2020-10-13
IL278423A (en) 2020-12-31
IL278423B2 (en) 2024-04-01
RU2017133273A (en) 2019-03-27
AU2021204211A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2022001757A (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer.
MX2018014435A (en) Pd-1 / pd-l1 inhibitors for cancer treatment.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
MX2022001447A (en) Combination therapies of hdac inhibitors and pd-l1 inhibitors.
MX2018008052A (en) Lsd1 inhibitors.
PH12016501550B1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
PH12015502091A1 (en) Cdc7 inhibitors
EA201691376A1 (en) COMBINATION OF ANTAGONIST PD-1 AND VEGFR INHIBITOR FOR CANCER TREATMENT
MX2016002273A (en) Treating cancer with a combination of a pd-1 antagonist and dinaciclib.
EA201890768A3 (en) TREATMENT OF MALIGNANT TUMOR INHIBITORS TOR-KINASE
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
MX2017009246A (en) Combination drug.
MX2017011018A (en) Inhibition of olig2 activity.
ZA201901367B (en) Inhibition of olig2 activity
MX2021004709A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor.
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
NZ727108A (en) Ezh2 inhibitors for treating lymphoma